When should I use reversal agents for NOACs?

Back

ESC Premium Access

When should I use reversal agents for NOACs?

Session: Reversal of NOACs' effect: when and how?

Topic: Drug therapy

Speaker: Professor G. Lip (Liverpool, GB)

Event: ESC Congress 2016

Congress Presentation

About the speaker

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

88 presentations

8 followers

3 more presentations in this session

Reversal of the thrombin inhibitor dabigatran.

Speaker: Associate Professor A. Niessner (Vienna, AT)

Reversal of FXa inhibitors.

Speaker: Associate Professor S. Wassmann (Munich, DE)

Access

ESC TV

Will the availability of specific reversal agents change the use of NOACs?

Speaker: Professor F. Verheugt (Amsterdam, NL)

Access the full session

Reversal of NOACs' effect: when and how?

Speakers: Professor G. Lip, Associate Professor A. Niessner, Associate Professor S. Wassmann, Professor F. Verheugt

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

When should I use reversal agents for NOACs?

About the speaker

Professor Gregory Yh Lip

3 more presentations in this session

Reversal of the thrombin inhibitor dabigatran.

Reversal of FXa inhibitors.

Will the availability of specific reversal agents change the use of NOACs?

Access the full session

Reversal of NOACs' effect: when and how?

About the event

ESC Congress 2016

ESC 365 is supported by